Hepatitis C Knowledge Network Webinar Series
|
|
- Dylan Cox
- 6 years ago
- Views:
Transcription
1 Hepatitis C Knowledge Network Webinar Series HCV Epidemiology: The Silent Epidemic Presented by: Michael Saag, MD, FIDSA IDSA Hepatitis Task Force Director, Center for AIDS Research University of Alabama at Birmingham June 28, 2013
2 Disclaimer Any diagnostic or therapeutic recommendations and all opinions expressed during the IDSA Hepatitis C Knowledge Network are those of the presenter only. They do not necessarily represent the views of IDSA. The webinar viewer must use their own independent professional judgment in making clinical decisions. The webinar viewer assumes all risks in using the information provided. IDSA will bear no legal liability for resulting use of the information provided during the webinar. The IDSA Hepatitis C Knowledge Network is in full compliance with HIPPA. 2
3 Introduction IDSA Hepatitis C Knowledge Network offers a monthly, hour-long webinar to educate IDSA members on the current recommended practices to treat and manage patients infected with the hepatitis C virus (HCV) Provides information on the critical knowledge topics to effectively identify, treat, and manage HCV Opportunity for HCV treaters to engage with HCV experts, discussing issues related to complex patient care and effective treatments To find out more, please visit: (Member Login Required) 3
4 Outline Epidemiology of Hepatitis C Virus (HCV) Morbidity and mortality of chronic hepatitis C (CHC) Special populations New CDC HCV screening recommendations Improving testing and linkage to care Era of advances in therapy for HCV 4
5 Large Global Burden of HCV Infection and Disease Global M chronic infections ~ 2.2 3% world population 27% of cirrhosis and 25% of HCC due to HCV 75% with HIV are co-infected with HCV in some countries (China, Vietnam, Russia) ~ 499,000 HCV-related deaths annually 3 to 4 million new infections with HCV each year Liver International pages 1-3, 8 JUN 2012 Lim SS, Lancet 2012; 3 Perz J Hepatol. 2006; 4 Zhuang X et al. Drug Alcohol Depend 2012; 5 Serano L etal. J Int Assoc Physicians AIDS Care 2012 Jul 24; 6 Pltt L et al. Eur J Public Health 2009.; 7 CDC. MMWR,
6 IOM 2010 Study Report Hepatitis and Liver Cancer: A National Strategy for the Prevention and Control of Hepatitis B and C ~ 5 million Americans chronically infected with HBV or HCV ~ 65 to 75 percent of the 5 million not aware of Dx ~ 150,000 Americans die from liver cancer (HCC) or end-stage liver disease (ESLD) associated HBV or HCV in the next decade The death rate from HCV expected to triple in the next 10 to 20 years Total medical costs for untreated HCV could more than double over the next 20 years from $30 to $80 B/yr 6
7 Hepatitis C Evolution Association Transfusion With Hepatitis Non-A, Non-B Concept Pegylated Interferon/ Ribavirin DAA Oral HCV (Chiron) Therapies: Protease Inhibitors Recognition Infectious Nature of Hepatitis Discovery of Hepatitis B Interferon Interferon Ribavirin Polymerase Inhibitors More HCV AB Test Beyond
8 Estimated Incidence of Acute HCV United States, Surrogate testing of blood donors Decline among transfusion recipients Anti-HCV test (1 st generation) licensed Anti-HCV test (2 nd generation) licensed Decline among injection drug users HIV Epidemic Recognized 1981 HIV Antibody Test licensed Sentinel Counties Study of Viral Hepatitis and State Disease Surveillance, CDC. Year 8
9 HCV Natural History Acute HCV Infection 75% Resolution ~ 30-40% mild-moderate symptoms Mortality rare from acute HCV Chronic HCV infection Normal ALT 70% Chronic hepatitis ~30% HCC incidence ~1-4% /year Cirrhosis HCC Death ESLD (Liver failure) ~5-7% /year 20 years 30 years 40 years Poynard. Lancet. 1997, Feld & Liang. Hepatology. 2006Santantonio T et al, J Hepatology. 2008;49: NIH Consensus Conference Statement, June 2002, John-Baptiste A et al, J Hepatology. 2010;53: Seeff LB, Liver International. 2009;29(suppl 1):89-99., 1 Freeman AJ et al, Hepatology 2001; 2 Norderstedt, et al. Dig Liv Dis 2010; 3 Hassan MM, et al. J.Clin, Gastroenterol 2002; 4 Rein et al, Dig Liver Dis 2011; Am J Epidemiology 2002; 5 Perz et al, J Hepatology 2006; 9
10 Projected Prevalence of HCV Disease Ever infected Chronic Hepatitis Cirrhosis Acute Hepatitis Davis, G. Gastroenterology 2010;513 10
11 Hepatocellular Carcinoma in the U.S. Since 1975, HCC incidence has tripled 1 HCC incidence increases Overall 3.5%/year Blacks 4.8% Whites 3.8% Persons years 9.1% 50% caused by HCV 3 Primary liver cancer mortality 1 increasing faster than other causes of cancer deaths 3 0 Hepatocellular Carcinoma Incidence: US, Rate per 100, Male Both Sexes Year of Diagnosis 1. Altekruse, et al. J Clin Oncol MMWR. 2010;59(17): Eheman, et al. Cancer
12 Long-Term US Mortality Trends with Average Annual Percentage Change By Cancer Site* Males Females Average Annual Percent Change From The Annual Report to the Nation on the Status of Cancer, J Natl Cancer Inst, Feb 6, 2013 * 10 year AAPC is statistically significant from 0 (p<.05) based on joinpoint model. Incidence data from SEER 13, mortality data from NCHS.
13 Age-Adjusted Rates of Mortality Associated with HBV, HCV, and HIV 7 United States, Rate per 100,000 Persons Hepatitis B Hepatitis C HIV Year In 2007, >70% of registered deaths in HCV-infected were aged yo Ly et al. Ann Int Med
14 Cause of Death by Age Group in U.S. Rank Accidents Malignancies Malignancies Heart 2 Malignancies Heart Heart Malignancies 3 Heart Accidents COPD Cerebrovasc 4 Suicide Cirrhosis/CLD Diabetes COPD 5 HIV Suicide Accidents Alzheimer 6 Homicide Cerebrovasc Cerebrovasc Pneumonia 7 Cirrhosis/CLD HIV Cirrhosis/CLD Diabetes 8 Cerebrovasc. Diabetes Suicide Accidents 9 Diabetes COPD CKD CKD 10 Pneumonia Viral hepatitis Septicemia Septicemia CDC. National Vital Statistics Reports 2009;
15 Monitor Case Reporting and HCV Mortality Years to Death from the Date of HCV Diagnosis Massachusetts: Number of deaths N=8,499 Median interval: 3 years Median age: 53 years < Years to death from date of HCV diagnosis A total of 76,122 HCV diagnoses were reported to the MDPH between 1992 and 2009, 8,499 of these reported HCV cases died and are represented in the figure V Lijewski, D Church, MA Dept of Health 15
16 HCV Testing Recommendations in United States Issued in 1998 CDC recommendations (1998) Ever injected illegal drugs Received clotting factors made before 1987 Received blood/organs before July 1992 Ever on chronic hemodialysis Evidence of liver disease (elevated ALT) Infants born to HCV infected mothers HIV infection USPSTF recommendations (2004) Rating I: Screening of high risk persons Rating D: General population screening MMWR. 1998;47 (No. RR-19). 16
17 Prevalence of HCV by Risks and Demographic Characteristics in the U.S NHANES Elevated HCV prevalence 57.5% IDU Only 17% reported injection in past year 5.8% Transfusion history 7.5% >20 lifetime sexual partners 3.0% Black 65.6% of those HCV+ born in Peak prevalence years Overall 4.3% Men 6.2% Blacks 9.4% Black men 13.6% Overall U.S. prevalence Prevalence of Anti-HCV 8% 7% 6% 5% 4% 3% 2% 1% 0% Anti-HCV 1.6% (4.1 million) Chronic HCV 1.3% (3.2 million) ALL Men Women Born ~ Age Group (years) Armstrong et al. Ann Intern Med
18 Knowledge of HCV Status Participants in NHANES, anti-hcv+ persons interviewed 86 (51%) unaware of their infection prior to being tested in this survey 84 (49%) already knew their HCV status Reasons for previous testing (n=84) for anti-hcv included 46% routine physical/blood test 16% symptoms of hepatitis 10% blood donations 4% tested because of risk Denniston M, et al Hepatology
19 Best-C: A Retrospective Study of HCV Testing and Linkage to Care in 4 Primary Care Centers* Number with risk factors in medical record (2.6% patients)* (N=209,076) Percent tested Ever IDU n= 2,992 34% Hemophilia n= 1,241 24% HIV+ n= 1,240 62% 10.6% patients had elevated ALT or AST and no other risk indication 23.7% of these were tested for HCV antibody *Henry Ford Detroit;Mt Sinai, NYC; UAB, Birmingham; UT, Houston 19
20 HCV Test, Care, and Cure Continuum 120% 100% ~ 3 million persons living with HCV 80% 60% 40% 20% 0% 1.6 M (50%) 1.2 M (38%) 750,000 (23%) 360,000 (11%) 200,000 (6%) Holmberg S, et al, NEJM, 2013)
21 Limited Effectiveness of Risk-based HCV Testing Strategies: Missed Opportunities CDC 1998 risk-based recommendations include Injection drug use Blood transfusion before 1992 and other blood exposures HIV Barriers to HCV testing Provider knowledge and experience Providers may be reluctant to ask about risks Provider time constraints Patient may be reluctant to disclose or may not recall of long-past risk behavior Concerns of stigma 45-85% are unaware of their HCV infection Shehab TM. J Viral Hepat, Shehab TM, et al. Am J Gastroenterol, Serrante JM, et al. Fam Med, Shehab TM, et al. Hepatology, Roblin, et al. Am J Man Care Spradling, et al., Hepatology, Zapata et al, Ann Hepatology, 2010; Napper et al, AIDS Behav, 2010; Haley et al, Preven Med, 2002; Torrone et al, AIDS Pat Care, 2010; Volk et al,
22 Consideration for a Prevalence-Based Strategy To Focus Testing on Persons Born Prevalence 5.3 times higher than other ages (3.29% vs 0.55%) 1 Represents 81% of all adult chronic HCV infections 67% have medical insurance Infected population has modifiable disease co-factors ~ 50% consume 2 alcoholic drinks/day 80% lack Hep A/B vaccination 2 Represents 73% of all HCVassociated mortality Armstrong, et al. Ann Int Med Kramer, et al. Hepatol Ly, et al. Ann Int Med
23 Harms CDC Consultation August 2011 Evidence Based Review of the Recommendation Non-response to treatment (Failure to achieve SVR) Serious Adverse Events- significant but reversible Benefits Effect of Treatment-related clearance of HCV Reduces risk of HCC by 70% Reduces risk of all-cause mortality by 50% Effect of clinician-directed intervention on alcohol use Decline of alcohol use >38% for >1 year follow-up
24 Future Burden of Hepatitis C Related Morbidity and Mortality in U.S. Markov model of health outcomes Of 2.7 M HCV infected persons in primary care 1.47 M will develop cirrhosis 350,000 will develop liver cancer 897,000 will die from HCV-related complications Number Deaths DCC HCC Transplants Rein et al. Dig Liver Dis Year 24
25 25
26 CDC Recommendations for Prevention and Control of HCV infection and Chronic Diseases* Adults born during HIV-infected patients Persons who ever injected illegal drugs Persons who were ever on chronic (long-term) hemodialysis Persons who received clotting factor concentrates produced before 1987 Prior recipients of transfusions or organ transplants, before July 1992 Persons with persistently abnormal alanine aminotransferase levels Health care, emergency medical, and public safety workers after needle sticks, sharps, or mucosal exposures to HCV-positive blood Children born to HCV-positive women *17, 2012, MMWR 26
27 USPSTF Recommendations for HCV Testing June 2013 USPSTF recommends screening for HCV infection in adults at high risk including those with any history of intravenous drug use or blood transfusions prior to Grade B (moderate certainty that the net benefit is moderate to substantial) USPSTF recommends that clinicians consider offering screening for HCV infection in adults born between 1945 and Grade C (HCV screening has at least a small net benefit) Grade A/B no-copay preventive service, a priority for performance measurement 27
28 HCV Infection, Past or Present Case Definitions 2012 Clinical Presentation No symptoms are required Laboratory Criteria Anti-HCV positive (repeatedly reactive) by EIA (enzyme immunosorbant assay) verified by at least one additional more specific assay, OR Positive HCV RIBA (Recombinant ImmunoBlot Assay), OR Positive HCV NAT (nucleic acid test, RNA or genotype) OR Anti-HCV positive with predictive s/co 28
29 Hepatitis C Virus (HCV) Infection Testing Algorithm Simplified to Detect Current Disease* ANTI-HCV Point-of-care immunoassay (Rapid Test) or Bench immunoassay (EIA, CIA, MEIA, CMIA) REACTIVE (+) NEGATIVE (-)* NAT for HCV RNA NEGATIVE (-)** STOP POSITIVE (+) Active / Current HCV infection Refer to Care and Treatment # If immunocompromized status or acute infection is suspected, then test for HCV RNA. # # If ongoing risk factors (e.g.. injecting drug use or other recent exposures) repeat anti-hcv testing >6 months after most recent exposure *CDC, 2012, Published Vital Signs, MMWR,
30 Cost of HCV Diagnostic Tests Interpretation Anti-HCV (EIA) HCV RNA HCV Genotype Hepatitis C Resolved/ False positive + - NA McGarry et al $30 $83 NA Eckman et al $20 $50-60 $360 McGarry. Hepatology 2012; 1344, Eckman Clinical Inf Dis 2013, in press 30
31 Eradication of HCV Is Durable and Reduces Liver Failure, HCC, and Death Van der Meer JAMA 2012; Backus Clin Gastro 2011; Imazeki Hepatology 2003; Shiratori Ann Intern Med 2005; Veldt et al Ann Intern Med 2007; Berenguer Hepatology 2009; 31
32 Eradication of HCV Is Durable and Reduces Liver Failure, HCC, and Death Van der Meer JAMA 2012; Backus Clin Gastro 2011; Imazeki Hepatology 2003; Shiratori Ann Intern Med 2005; Veldt et al Ann Intern Med 2007; Berenguer Hepatology 2009; 32
33 Efficacy of HCV Treatment on Viral Eradication Average Sustained Viral Response (SVR) Rates from Clinical Trials % SVR IFN 6m IFN 12m I/R 6m Modified from Strader. Hepatology 2004;39:1147 I/R 12m p-ifn 12m p-ifn/r 12m PI/I/R 6-12m Perfectovir DAAs/PI/R or 33 All Oral DAA combos
34 Potential Impact on Future Burden of Hepatitis C Related Mortality in the US HCV deaths prevented 143, , ,00 714,000 No Testing treat 15% treat 25% treat 50% treat 75% Rein,D., HCV Payer Panel 2013
35 Summary The prevalence of chronic hepatitis C is large Many, if not most, persons living with chronic hepatitis C remain undiagnosed Screening and linkage to care, evaulation, and treatment must improve to realize health gains anticipated from new therapies The burden of HCV-related morbidity and mortality is large, growing, and associated with health disparities A one-time HCV test for persons born is a cost-effective approach to reduce HCV morbidity and mortality HCV care and treatment can cure infection and prevent adverse health outcomes Collaboration among public health, clinical care providers, laboratories and payers is essential to improve HCV testing and linkage to care and treatment We can control and eventually eliminate HCV transmission and disease
36 Acknowledgements CDC John Ward, MD Bryce Smith, PhD Cynthia Jorgenson, DrPH Scott Holmberg, MD Bernie Branson, MD Amy Remick, MBA David Rein, NORC Carol Brosgart, MD Quest Rick Pesano, MD AASLD and IDSA Ira Jacobson, MD Don Jensen, MD Maribel Rodriguez-Torres, MD Ray Kim, MD Anna Lok, MD David Thomas, MD Mark Sulkowski, MD 36
Hepatitis C in the United States : Preparing for the Test and Cure Era
Hepatitis C in the United States : Preparing for the Test and Cure Era Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Centers for Disease Control and Prevention
More informationStrategies to Address HCV
Strategies to Address HCV HIV Programs & U.S. Viral Hepatitis Action Plan Corinna Dan, RN, M.P.H. Viral Hepatitis Policy Advisor Office of HIV/AIDS and Infectious Disease Policy September 10, 2015 1 The
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationCDC PUBLIC HEALTH GRAND ROUNDS. The 25th Anniversary of the Discovery of the Hepatitis C Virus Looking Back to Look Forward
CDC PUBLIC HEALTH GRAND ROUNDS The 25th Anniversary of the Discovery of the Hepatitis C Virus Looking Back to Look Forward June 17, 2014 1 The Epidemiology of Hepatitis C How Did We Get Here? John W. Ward,
More informationEpidemiology and Screening for Hepatitis C Infection
Epidemiology and Screening for Hepatitis C Infection Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Epidemiology/Screening for Hepatitis
More informationHEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38
2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally
More information26/09/2014. Types of Viral Hepatitis. Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges
Rate per, Types of Viral Hepatitis A E B D C Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges Source of virus Feces Feces Blood/bloodderived body fluids
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationHCV in the Latino Community -Epidemiology, Natural History, Risk Factors, Screening and Diagnosis
HCV in the Latino Community -Epidemiology, Natural History, Risk Factors, Screening and Diagnosis Wari Allison MD, PhD Assistant Professor/Research Dept. of Medicine/Infectious Disease Medical Director
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #400 (NQF 3059): One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationHepatitis C Best Practice Guidelines For Local Health Departments
Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationSharing the Message of Hepatitis C and Liver Cancer in Indian Country
Sharing the Message of Hepatitis C and Liver Cancer in Indian Country Jessica Leston, DrPH (c), MPH Northwest Portland Area Indian Health Board Clinical Programs Director - HIV/HCV Objectives Describe
More informationNumbers HCV and HIV Epidemiology in the US
By The Numbers HCV and HIV Epidemiology in the US Coinfection Fridays Session 1 18 January 2019 Christopher B. Hurt, MD Associate Professor of Medicine Co-Director, North Carolina AIDS Training & Education
More informationHepatitis C Cure The Invisible Epidemic
Hepatitis C Cure The Invisible Epidemic Iris House 8 Th Annual Face of AIDS Summit Hadiyah Charles Hepatitis Advocacy Manager Harm Reduction Coalition Hepatitis C Basics A virus that can cause chronic
More informationHepatitis C Virus. https://www.labcorp.com/wps/wcm/connect/labcorp+content/labcorp/education+and+re...
Page 1 of 16 Hepatitis C Virus Data reflected in this report are based solely on the collection of samples submitted to LabCorp for testing. Refer to the limitations section of this report for additional
More informationHCV Vaccine Development
HCV Vaccine Development Andrea L. Cox, MD,PhD Professor of Medicine and Oncology Viral Hepatitis Center Disclosure speaker interests Disclosure of speaker interest No potential conflicts to report HCV-
More informationHepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm
Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis
More informationHepatitis C Virus (HCV)
Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationDigestive & Liver Disease Wellness
Digestive & Liver Disease Wellness Colorectal Cancer Screening & Prevention According to the American Cancer Society, this year 136,830 people in the U.S. According will be to diagnosed the American with
More informationManagement of Acute HCV Infection
Management of Acute HCV Infection This section provides guidance on the diagnosis and medical management of acute HCV infection, which is defined as presenting within 6 months of the exposure. During this
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hepatitis_c 1/1/2019 N/A 1/1/2020 1/1/2019 Description of Procedure or Service Description Hepatitis C is
More informationZobair M. Younossi M.D., M.P.H., FACG
HCV Epidemiology and Cohort Screening Guidelines Zobair M. Younossi, MD, MPH, FACG Consultant or Advisor: Conatus, Enterome, Gilead, Merck, Salix, Vertex, J & J HCV Epidemiology and Cohort Screening Guidelines
More informationTHE CHANGING LANDSCAPE OF HEPATITIS INFECTION. Michael E. Herman D.O.
THE CHANGING LANDSCAPE OF HEPATITIS INFECTION Michael E. Herman D.O. What s New? For Primary Care Providers Importance of diagnosing HCV For HCV Treaters How can we improve current therapies? For everyone
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10 13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10 13, 2016 Disclosures: Hep C Update N. Randy Kolb, MD Speakers has received Funding
More informationC 肝職業暴露後之處置 衛福部疾病管制署 中區傳染病防治醫療網 王任賢指揮官
C 肝職業暴露後之處置 衛福部疾病管制署 中區傳染病防治醫療網 王任賢指揮官 HCV:Structure and Classification Unclassified virus, Member of the flavivirus family (other members yellow fever and dengue) Enveloped single stranded RNA virus Humans
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationSTOP Hepatocellular Carcinoma
STOP Hepatocellular Carcinoma Laura Tenner MD MPH, Amit G. Singal MD MS, Mamta Jain MD, Barbara Turner MD, Barbara Riske MS ReACH Center and Dept of Medicine UT Health San Antonio Dept of Medicine UT Southwestern
More informationi Screening and Natural History
HCV Epidemiology, i Screening and Natural History BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Hepatitis
More informationChronic viral hepatitis and liver disease in Belgium Pierre Deltenre
Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Brussels, November 7, 2017 Hepatitis B and C in Belgium What we need to know 1. Who is at risk of infection? 2. What is the natural
More informationA "State-of-the-Art" Conference Hepatitis C: A Meeting Ground for the Generalist and the Specialist
A "State-of-the-Art" Conference Hepatitis C: A Meeting Ground for the Generalist and the Specialist Information regarding pathogenesis and appropriate management of chronic hepatitis C continues to evolve.
More informationHepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious Disease & Laboratory Sciences
Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences Hepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationHCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
More informationIntegrating Hepatitis C into Drug Treatment Settings
Integrating Hepatitis C into Drug Treatment Settings Substance Use Disorders Statewide Conference August 24, 2017 Pomona, CA Christine Rodriguez, MPH California Department of Public Health 1. Hepatitis
More informationImproving Access & Linkage to Care in Underserved Populations & Baby Boomers
Improving Access & Linkage to Care in Underserved Populations & Baby Boomers Lesley Miller MD Medical Director, Grady Liver Clinic Associate Professor of Medicine Division of General Medicine and Geriatrics
More informationHepatitis C Infection and the Opportunity for Eradication
Hepatitis C Infection and the Opportunity for Eradication Dawn Fishbein, MD, MS Scientific Director, Viral Hepatitis Research MedStar Health Research Institute Women in Government Healthcare Summit November
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationHEPATITIS C BASICS ILAN S. WEISBERG, MD DIRECTOR HEPATOLOGY LENOX HILL HOSPITAL JUNE 20, 2015
HEPATITIS C BASICS ILAN S. WEISBERG, MD DIRECTOR HEPATOLOGY LENOX HILL HOSPITAL JUNE 20, 2015 Overview Understand the GLOBAL and US burden of chronic HCV infec
More informationNIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:
ABC s of Hepatitis C Treatment Today Elizabeth N. Britton, MSN, FNP-BC Hepatology Services Louisiana State University Health Sciences Center ebritt@lsuhsc.edu ANAC CONFERENCE -TUCSON NOV 2012 Hepatitis
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationObstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis
Obstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis Jonathan Mermin, MD, MPH National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease Control and
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationHepatitis C Elimination: Screening, Linkage and Treatment. Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas
Hepatitis C Elimination: Screening, Linkage and Treatment Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas Hepatitis C: Worldwide Presence Worldwide prevalence: 130-150 million Viral hepatitis
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationUpdates in the Treatment of Hepatitis C
Disclosures Updates in the Treatment of Hepatitis C Arslan Kahloon M.D Assistant Professor of Medicine University of Tennessee, Chattanooga I have no conflicts of interest or financial sponsorship to disclose
More informationPrevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD
Prevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD Hello, my name is Milena Gould Suarez, and today I will present "Prevent Hepatocellular
More informationGeo-epidemiology of Hepatitis C in Northeast Indiana
Geo-epidemiology of Hepatitis C in Northeast Indiana Shori Gerardot, Ashley Cross, Atit Patel, Kassidy Beck MS, Scott M. Stienecker MD, and Teresa A. Beam PhD Hepatitis C (HCV) ~180 million worldwide ~2.7-3.9
More informationUpdate on HIV-HCV Epidemiology and Natural History
Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,
More informationHepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT
Hepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT Background and affiliations BS (MIT); 3 years in international health (Mexico City and Honduras with Peace Corps); MS (Colorado State University);
More informationThe ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses
The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection
More informationHepatitis B Epidemiology and Prevention in the Elimination Era John W. Ward, MD
Hepatitis B Epidemiology and Prevention in the Elimination Era John W. Ward, MD Director, Program for Viral Hepatitis Elimination, Task Force for Global Health Senior Scientist, National Center for HIV/AIDS,
More informationANTIVIRAL THERAPY FOR HCV. Alfredo Alberti
CLINICAL IMPACT OF SVR AFTER ANTIVIRAL THERAPY FOR HCV Alfredo Alberti Department of Histology,Microbiology and Medical Biotechnologies Molecular Hepatology Unit Venetian Institute of Molecular Medicine
More informationHCV epi overview. Brigg Reilley, NPAIHB, Nat l Program Epidemiologist,
HCV epi overview Brigg Reilley, NPAIHB, Nat l Program Epidemiologist, brigg.reilley@ihs.gov In 20 minutes, we will cover Transmission/trends Screening HCV estimates: national, IHS, OK (federal), Cherokee
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationWelcome to A Chronic Disease You Can Cure: Hepatitis C Treatment for Primary Care Providers Conference February 24, 2018
Welcome to A Chronic Disease You Can Cure: Hepatitis C Treatment for Primary Care Providers Conference February 24, 2018 Approved Provider Statements: ANTHC is accredited by the Washington State Medical
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationHepatitis STARS Program. Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003
Hepatitis 2003 STARS Program Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003 Outline n Hepatitis A Epidemiology and screening Transmission n Hepatitis B Epidemiology
More informationHepatocellular Carcinoma (HCC): Burden of Disease
Hepatocellular Carcinoma (HCC): Burden of Disease Blaire E Burman, MD VM Hepatology Hepatocellular Carcinoma (HCC) Primary HCCs most often arise in the setting of chronic inflammation, liver damage, and
More information@PremierHA #AdvisorLive. Download today s slides at
@PremierHA #AdvisorLive Download today s slides at www.premierinc.com/events Logistics Audio Use your computer speakers or dial in with the number on your screen Notes Download today s slides from the
More informationHepatitis C (Hep C) By Joshua Rollins. Transmission/Reservoirs
Hepatitis C (Hep C) By Joshua Rollins Etiological Agent: Hepatitis C virus (HCV) Transmission/Reservoirs Reservoir: Human The infection stems from the Hepatitis C virus (HCV), which is Blood borne pathogen
More informationExploring the risks of liver cancer after successful treatment for hepatitis C virus
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring the risks of liver cancer after successful treatment for hepatitis C virus 11 June 2013 In Canada and other high-income countries,
More informationEconomic Impact of Hepatitis C: Highlights of Cost-Effectiveness Modeling. Presented at: Viral Hepatitis Action Coalition Biannual
Economic Impact of Hepatitis C: Highlights of Cost-Effectiveness Modeling Presented at: Viral Hepatitis Action Coalition Biannual Meeting Atlanta, GA May 15, 2013 Overview Cost-effectiveness review AIM
More informationKaren E. Kim, MD Professor of Medicine Dean for Faculty Affairs Director, Center for Asian Health Equity University of Chicago
Karen E. Kim, MD Professor of Medicine Dean for Faculty Affairs Director, Center for Asian Health Equity University of Chicago 1 2 billion people have been exposed to HBV 350-400 million people chronically
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationHepatitis C. No disclosures. 1. The USPSTF recommends Hepatitis C screening in which patient populations?
Hepatitis C Jennifer Acosta PA-C No disclosures 1. The USPSTF recommends Hepatitis C screening in which patient populations? a. All adults at least once b. Immigrants to the US and those over age 65 c.
More informationHEPATITIS C TREATMENT UPDATE
HEPATITIS C TREATMENT UPDATE Hepatitis C: Burden of Disease in USA HCV is generally asymptomatic until advanced liver disease 4.1 million persons ever infected; 3.2 million chronic infections Up to 75%
More informationDefinition: Active injection drug users - Those who have injected any drug(s) within the 12 month reporting period
Quality ID #387 (NQF 3060): Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL
More informationHepatitis C. Surveillance Protocol. Infectious Disease Epidemiology Program. Provider Responsibilities
January 2007 Hepatitis C Provider Responsibilities 1) Report newly diagnosed persons with acute hepatitis C by completing the provider and laboratory (yellow and green) sections of the WVEDSS form. Forward
More informationA Practical Guide to Hepatitis C Management
A Practical Guide to Hepatitis C Management David C. Wolf, M.D., FACP, FACG, AGAF Medical Director of Liver Transplantation Westchester Medical Center Professor of Clinical Medicine New York Medical College
More informationHIV coinfection and HCC
HIV coinfection and HCC 3 rd APASL STC on HCC 21 st -23 rd Nov 2013 Cebu, Phillippines George KK Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond) Consultant, Humanity and Health GI
More informationHepatitis C: Let s Talk About It. Causes of Hepatitis
Hepatitis C: Let s Talk About It Susan Thompson, RN, MPH Technical Assistance and Training Program NC Communicable Disease Branch July 2012 Causes of Hepatitis any swelling, inflammation, or irritation
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationRecommendations for Hepatitis C Screening
Hepatitis C Online PDF created June 16, 2018, 9:14 am Recommendations for Hepatitis C Screening This is a PDF version of the following document: Module 1: Screening and Diagnosis of Hepatitis C Infection
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationPrimary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis
More informationHEPATITIS C : RECENT ADVANCES IN SCREENING & MANAGEMENT
HEPATITIS C : RECENT ADVANCES IN SCREENING & MANAGEMENT 6/27/2014 C Stands for Cure. Kirti Shetty, MD Associate Professor Of Medicine Director Of Hepatology National Capital Region 1 DISCLOSURES Grant
More informationHepatitis C: Surveillance, Case Definition, and Investigation
Hepatitis C: Surveillance, Case Definition, and Investigation Tuesday, November 14, 2017 10am 11:30am NJ Department of Health Communicable Disease Service Welcome to the Webinar Today s webinar is being
More informationAssessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY
Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY Disclosures Nothing to Disclose Assessing the patient with a new diagnosis of Hepatitis
More informationHepatitis situation in the Republic of Macedonia
Hepatitis situation in the Republic of Macedonia Presented by Viktorija Chaloska Ivanova University Clinic of Gastroenterology Skopje, Republic of Macedonia Hepatitis Prevalence/incidence in Macedonia
More informationThe Cost-Effectiveness of Birth Cohort and Universal Hepatitis C Antibody Screening in U.S. Primary Care Settings
September 2011 The Cost-Effectiveness of Birth Cohort and Universal Hepatitis C Antibody Screening in U.S. Primary Care Settings Technical Report Prepared by David B. Rein John S. Wittenborn RTI International
More informationManagement of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER
Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines
More informationTreatment of Patients with HCV and HIV
Treatment of Patients with HCV and HIV BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Four Questions Is HIV/HCV
More informationNational Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission - United States
More informationHepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18
Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis
More information-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual
2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein
More informationNew York State HCV Provider Webinar Series
New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Dost Sarpel, MD Division of Infectious Disease Viral Hepatology Milford Regional Medical Center Objectives Review the epidemiology
More informationInternist Diagnosis and Management of Chronic Hepatitis B Virus Infection
UPDATE IN OFFICE MANAGEMENT Internist Diagnosis and Management of Chronic Hepatitis B Virus Infection Brian J. McMahon, MD, a Joan Block, RN, BSN, b Barbara Haber, MD, c Thomas London, MD, d James A. McHugh,
More informationAfter the Cure: Looking Ahead in HCV Management. Nancy Reau, MD
After the Cure: Looking Ahead in HCV Management Nancy Reau, MD Objectives 1. Discuss current recommendations in HCV screening, performance and limitations 2. Discuss linkage to care, hurdles and strategies
More informationHCV Infection in the United States
New York State Department of Health HCV Infection in the United States ~4 million in the U.S. infected with chronic hepatitis C virus (HCV) 17,000 new infections per year 75 percent of adults with hepatitis
More informationHepatitis C Screening For Baby Boomers in Primary Care. Nicole Mesick DO, RD NHAFP Conference May 18 th, 2018
Hepatitis C Screening For Baby Boomers in Primary Care Nicole Mesick DO, RD NHAFP Conference May 18 th, 2018 Disclosures No disclosures Objectives Recognize the importance of diagnosing Hepatitis C (HCV)
More informationIs Elimination of Hepatitis C Possible?
Is Elimination of Hepatitis C Possible? JORGE MERA, MD CHEROKEE NATION DISCLOSURE INFORMATION The presenter has nothing to disclose. Outline Scope of the problem Definitions Is elimination of HCV needed?
More informationAn HCV Vaccine: Can we get there?
An HCV Vaccine: Can we get there? Andrea L. Cox, MD,PhD Viral Hepatitis Center No Conflicts of Interest Outline Reasons to develop an HCV vaccine What constitutes protective immunity to HCV What challenges
More informationEpidemiology of Pathogenesis of HCV A Focus on HIV
Epidemiology of Pathogenesis of HCV A Focus on HIV Presented by MayaTech in conjunction with Dr. Camilla Graham, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA Our Speaker Dr.
More informationHepatitis C No Barriers to Cure
2018 Digestive Diseases Conference Kansas Hepatitis C No Barriers to Cure Dr. Mauricio Lisker Melman Professor of Medicine Director Hepatology Program Division of Gastroenterology Disclosure The following
More information